Brokers Set Expectations for Exact Sciences FY2026 Earnings

Exact Sciences Co. (NASDAQ:EXAS - Free Report) - Research analysts at Leerink Partnrs upped their FY2026 earnings per share estimates for shares of Exact Sciences in a research note issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will earn $0.81 per share for the year, up from their previous estimate of $0.80. The consensus estimate for Exact Sciences' current full-year earnings is ($1.10) per share.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The firm had revenue of $708.66 million during the quarter, compared to the consensus estimate of $716.80 million. Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. Exact Sciences's revenue was up 12.8% on a year-over-year basis.

A number of other research analysts have also weighed in on the company. Bank of America decreased their target price on Exact Sciences from $75.00 to $72.00 and set a "buy" rating on the stock in a report on Friday, December 13th. Raymond James reiterated a "market perform" rating on shares of Exact Sciences in a report on Thursday, September 26th. Piper Sandler cut their target price on shares of Exact Sciences from $85.00 to $75.00 and set an "overweight" rating for the company in a research note on Monday, November 11th. Sanford C. Bernstein upped their price target on shares of Exact Sciences from $75.00 to $90.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Finally, Robert W. Baird cut their price objective on shares of Exact Sciences from $70.00 to $67.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $72.76.

Exact Sciences Stock Performance

NASDAQ EXAS traded up $0.34 during trading on Wednesday, reaching $55.13. 3,535,098 shares of the company's stock were exchanged, compared to its average volume of 2,815,564. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. The business has a 50 day moving average price of $57.41 and a 200-day moving average price of $59.32. The stock has a market capitalization of $10.20 billion, a P/E ratio of -47.12 and a beta of 1.24. Exact Sciences has a fifty-two week low of $40.62 and a fifty-two week high of $79.62.

Institutional Investors Weigh In On Exact Sciences

Hedge funds have recently made changes to their positions in the stock. Huntington National Bank grew its holdings in shares of Exact Sciences by 838.1% during the third quarter. Huntington National Bank now owns 394 shares of the medical research company's stock worth $27,000 after purchasing an additional 352 shares during the last quarter. RPg Family Wealth Advisory LLC acquired a new stake in Exact Sciences during the 3rd quarter worth approximately $34,000. Capital Performance Advisors LLP bought a new stake in Exact Sciences during the 3rd quarter worth approximately $35,000. Modus Advisors LLC acquired a new position in Exact Sciences in the 4th quarter valued at approximately $43,000. Finally, Vestor Capital LLC bought a new position in shares of Exact Sciences during the third quarter valued at $46,000. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, CEO Kevin T. Conroy bought 19,500 shares of the firm's stock in a transaction on Wednesday, November 13th. The shares were purchased at an average price of $51.35 per share, for a total transaction of $1,001,325.00. Following the completion of the transaction, the chief executive officer now directly owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. The trade was a 1.85 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 1.36% of the company's stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.